Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA put a hold on the clinical trial of its ropinirole implant and told the company to submit more information to the federal watchdog.
After it completed an initial review of the implant’s Investigational New Drug application, the FDA asked Titan for final release test data on its ropinirole implant and the applicator used to insert the implant. Titan also needs to identify a principal investigator for the study, although the company said it is in the process of qualifying the participating clinical sites.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA asks Titan for more info before clinical trial of ropinirole implant appeared first on MassDevice.
from MassDevice http://ift.tt/2mGYPWb
Cap comentari:
Publica un comentari a l'entrada